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Abstract
Background: Japanese encephalitis virus (JEV) is a mosquito-borne flavivirus that causes Japanese Encephalitis (JE) and
Acute Encephalitis Syndrome (AES) in humans. Genotype-I (as co-circulating cases with Genotype-III) was isolated in
2010 (JEV28, JEV21) and then in 2011 (JEV45) from Midnapur district, West Bengal (WB) for the first time from clinical
patients who were previously been vaccinated with live attenuated SA14-14-2 strain. We apply bioinformatics and
immunoinformatics on sequence and structure of E protein for analysis of crucial substitutions that might cause the
genotypic transition, affecting protein-function and altering specificity of epitopes.
Results: Although frequency of substitutions in E glycoprotein of JEV28, JEV21 and JEV45 isolates vary, its homologous
patterns remain exactly similar as earlier Japan isolate (Ishikawa). Sequence and 3D model-structure based analyses of E
protein show that only four of all substitutions are critical for genotype-I specific effect of which N103K is common
among all isolates indicating its role in the transition of genotype-III to genotype-I. Predicted B-cell and T-cell epitopes
are seen to harbor these critical substitutions that affect overall conformational stability of the protein. These epitopes
were subjected to conservation analyses using a large set of the protein from Asian continent.
Conclusions: The study identifies crucial substitutions that contribute to the emergence of genotype-I. Predicted
epitopes harboring these substitutions may alter specificity which might be the reason of reported failure of vaccine.
Conservation analysis of these epitopes would be useful for design of genotype-I specific vaccine.
Keywords: Japanese encephalitis virus, Genotype I, Genotype III, Midnapur, Homology model, SNP Energetics,
B-cell & T-cell epitopes, PEP-FOLD, Docking
Background
Japanese encephalitis virus (JEV), a mosquito-borne fla-
vivirus of the family Flaviviridae, is the sole etiologic
agent of Japanese encephalitis (JE). JE is the neurotropic
disease has been the primary health concern in human
worldwide mostly affecting children and older person.
Approximately 25–30% of JEV cases are fatal and 50%
result in permanent neuropsychiatric sequelae [1, 2].
In India, JE was first reported in Vellore in 1955 [1, 2].
Since then, epidemics of JE in different states have been
reported including large and severe outbreak in the State of
Uttar Pradesh (UP) and part of Bihar that caused 5737 JE
cases and 1,334 deaths in UP and 360 cases with 64 deaths
in Bihar in 2005 [1]. Analyses showed that genotype III
(GIII) is predominant in India. However, genotype I (GI)
has recently been introduced in different States in India
including West Bengal [2]. Since 1973, JE outbreaks have
been recorded in different districts of West Bengal (WB).
Although, The State Health Department, Govt. of WB rou-
tinely conducts vaccination program (live attenuated SA14-
14-2, GIII) against JE cases in different districts of WB,
sporadic JE cases and deaths are being reported every year.
The vaccination program is challenged by the repeated
observation of co-circulation cases of GIII and GI in prevac-
cinated patients in the district of Midnapur of WB [3, 4].
Viral genome produces single polyprotein which is proc-
essed by viral and host proteases into structural (capsid C,
precursor membrane prM and envelope E) and non-
structural (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5)
proteins [5, 6]. Although all these proteins are important
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for viral life cycle, the E protein is responsible for host cell
interaction, infectivity and entry of the virus [6]. Amino
acid sequence of full length genome of virulent wild-type
(WT) JEV strain (SA14) when compared with that of non-
virulent live-attenuated SA14-14-2 vaccine strain, it was
found that a multitude of mutations are accumulated
throughout the genome of the later. These genome wide
mutations are collectively considered to be responsible for
non-virulent property of SA14-14-2. E protein accumulates
maximum number of mutations in the attenuation process
and thus it is considered as the primary genetic determin-
ant for neurovirulence and neuroinvasiveness of WT strains
of JEV [5, 7]. However, detailed mechanism for neuroviru-
lence and neuroinvasiveness in relation to locus specific
amino acid changes is unknown.
E protein based phylogenetic analyses have established
five different genotypes of JEV of which GIII constitutes the
major genotype in Asian countries including China, Japan,
Taiwan, India, Korea, Thailand, Indonesia, and Vietnam.
Genotyping is commonly achieved by construction of
phylogenetic tree using E protein of isolates and obtaining
clades [8]. Although in low frequency, GI is seen to replace
the existing GIII from all these countries [9]. In India like
other countries, GIII is the dominant genotype for all states.
However, co-circulation of GI with GIII in AES/JE patients
was first documented from Gorakhpur/UP/India region in
2009 [9] and then from Midnapur district of West Bengal
(WB), India in 2010 and 2011 [3, 4]. In the later case emer-
gence of GI with GIII was observed in patient even when it
was reported to be immunized with SA14-14-2 vaccine
prior infection [4, 10]. Similar observation is also available
from China [11].
In general the sequence of E protein of virulent isolate of
JEV is compared with that of non-virulent SA14-14-2 to
gain insight into neurovirulence and neuroinvasiveness ef-
fects of the former. While high neurovirulence of WT JEV
isolates was reported to be contributed by eight mutations
(F107L, K138E, V176I, A177T, H264Q, M279K, V315A
and R439K) in E protein, neuroinvasiveness involves muta-
tions in other proteins also [12–15]. Notably both GI
(JEV45) and GIII (JEV46 and JEV47) isolates of WB were
demonstrated to be neurovirulent and possess the above
mutations in E protein [4]. Additional substitutions ob-
served in these isolates were claimed to have potential for i]
altering immunogenicity [based on HLA (Human leukocyte
antigen) class I specific decreased/increased binding scores]
and ii] escape of antibody neutralization based on their oc-
currence in known loop structures of E protein of West
Nile Virus and decreased/increased hydrophilicity values
[4]. However, the question that which among all mutations
may have relation with the observed genotypic transition,
alteration of epitope’s specificity and E protein function re-
mains to be worked out. Reported failure of conventional
vaccination and emergence of GI in the region needs
careful prediction of B-cell and T-cell epitopes to improve
immunization in the locality at high risk of disease.
In the present study we consider E protein of newly
emerged GI isolates from Midnapur/WB to develop hom-
ology model structures possessing either all or single mu-
tation. We then use both mutant structure and sequence
based methods to identify critical among all acquired sub-
stitutions. Linear as well as conformational B-cell and T-
cell (HLA class I and II specific) epitopes are also been
worked out. We further report improved filtering of
epitopes using conservation, accessibility, conformational
stability and docking criteria. Using large database of E
protein from Asian countries, genotypic diversity of the
epitopes is established in this study. Taken together, the
study identifies GI specific critical SNPs and epitopes and
finds application in immunoinformatics.
Methods
Protein sequence retrieval and analysis
Full length nucleotide sequences of E protein that are
isolated from Midnapur district, WB, India as GI were
retrieved from GenBank database [ID: JN703381 (JEV28/
2010); JN703382 (JEV21/2010); KC526872 (JEV45/2011)].
We also procured Ishikawa/Japan GI [ID: AB051292] for
comparison. The nucleotide sequences were converted
into proteins using EMBOSS (European Molecular Biology
Open Software Suite) Transeq tool [16]. Primary structure
analysis was performed using our laboratory procedures
PHYSICO and PHYSICO2 [17, 18]. Secondary structure
analysis was performed using SOPMA [19].
Homology modeling, energy minimization, evaluation
and submission
Homology modeling, energy minimization and evaluation
have been routine procedures for many proteins [20–23].
Crystal structure of JEV ecto domain of E protein of SA14-
14-2 (GIII) is available in the Protein Data Bank (PDB) with
ID 3P54.pdb (Chain A, Resolution 2.1 Å). The PDB se-
quence (UNIPROT ID: P27395) has 97.3, 96.3, 96.3 and
95.3% identity with that of JEV28 (JN703381), JEV21
(JN703382), JEV45 (KC526872) and Ishikawa (AB051292)
isolates respectively. There is no INDEL region for any of
these sequences when aligned with reference template
sequence (P27395). We therefore performed homology
modeling on the target sequences using 3P54_A as tem-
plate. Comparative model of the target sequences were
achieved by MODELLER 9 v11 package [24] that makes
use of spatial restraints and other optimization procedures.
Alignments between template and target sequences were
performed by using MODELLER in-built script. Manual
improvements were incorporated in the alignment when it
was necessary. At least five replicates of model were pro-
duced of which the best model was selected based on
Discrete Optimized Protein Energy (DOPE) [25] assessment
Banerjee et al. BMC Immunology  (2017) 18:13 Page 2 of 16
scores. Idealization of bond geometry, optimization of loop
regions and removal of unwanted non-bonded contacts of
the initial model was achieved by energy minimization
using CHARMM (Chemistry at HARvard Macromolecular
Mechanics) force field of NAMD (Nanoscale Molecular
Dynamics) package [26]. To retain known disulfide bond
specificity, protein's residue pairs are appropriately patched.
Explicit water box of 5 Å additional distance from the high-
est coordinate in each dimension with an exclusion radius
2.4 Å was incorporated with the model using VMD (Visual
molecular dynamics) in-built solvate v1.5 plugin [27] and
subjected for minimization. After 5000 steps of conjugate
gradient minimization, trajectory analyses were performed
by using Vega ZZ interface [28] to select the lowest energy
frame of models. The resulted models were then subjected
for a series of tests such as stereo-chemical analyses by
PROCHECK [29] geometric relationship among non-
bonded atoms by ERRAT [30], proper threading of target
sequence with the model structure by VERIFY3D [31] and
structural features based overall quality by ProQ. [32]. Ion-
pair specificity and energetics of models and template were
compared using SBION [33], SBION2 [34] and ADSBET2
[35]. High quality models thus obtained were deposited in
the Protein Model Data Base (PMDB) [36] and the PMDB
identifiers were assigned as PM0080323, PM0079295,
PM0080324 and PM0080325 for JEV28, JEV21, JEV45
and Ishikawa respectively.
We also developed model for each positional mutation
observed in GI's E protein. In this procedure, we first gen-
erated target sequence from template (3P54_A) by giving
one observed mutation at a time. The derived target
sequence was then used for model development as de-
scribed. Each model was evaluated as mentioned above.
These mutant structures were used along with the tem-
plate (WT) to evaluate the effect of mutation (see below).
Disease related SNP prediction
The single nucleotide polymorphism occurring in the pro-
tein coding region may lead to deleterious consequences
and might affect epitopes conformational properties in
protein. In order to identify disease-associated SNPs, we
used SIFT [37], PhD-SNP [38] SNAP [39] and META-
SNP [40] authentic web server for sequence based and
SDM (Site Directed Mutator) [41] web server for structure
based prediction. SIFT prediction is based on the se-
quence homology and the physicochemical properties of
amino acids which are dictated by the substituted amino
acid. PhD-SNP uses support vector machines method
based human deleterious SNP. It predicts whether the
given amino acid substitution leads to disease associated
or neutral. META-SNP is a high accuracy integrated
method to discriminate between disease-related and poly-
morphic non-synonymous single nucleotide variants.
SDM is a statistical method for calculation of difference in
free energy between wild type and mutant protein and
prediction of disease association.
B-cell and T-cell epitope prediction
Prediction of both B cell and T cell epitopes is the first
step for rational vaccine design. Sequences of E protein
of GI isolates (Ishikawa, JEV28, JEV21 and JEV45) were
used for prediction of B-cell linear epitopes using
BCPREDS v1.0 [42] web server. Epitopes thus obtained
were subjected for further screening based on various
criteria such as i] model energy [43], ii] average side
chain accessibility using NACCESS procedure [44], iii]
Shannon Entropy based conservation properties [17, 18]
and iv] chances to harbor critical substitutions of epi-
topes. Finally only 8 epitopes were selected.
Conformational B cell epitopes are determined using high
accuracy web server EPSVR [45] using model 3D structures
as input. The method uses support vector regression for
prediction. The result file represents residues in color codes
from low (blue i.e. ≤40) to high (red i.e. ≥90). Only the high
possibility residues (≥80%) are highlighted in the model
structure using VMD interface [27].
Cellular peptide vaccine contains T-cell epitopes that
bind structurally to highly diverse, polygenic and poly-
morphic human MHCs (Major histocompatibility com-
plex) whose experimental determination are cost effective
and time consuming. IEDB analysis tools [46] were used
for MHC class specific (class I and II) T cell epitopes pre-
diction. All available MHC class specific HLA-alleles were
tested for their efficacy in binding epitopes under the strict
cutoff of percentile rank (equivalent to IC50 value). Clus-
tering of alleles against each top score epitope was per-
formed in excel. Epitopes were further short listed by their
antigenicity scores using VaxiJen v2.0 server [47]. MHC
class I epitopes were further screened based on proteoso-
mal processing score. Each set of epitopes were further
short listed using average conservation [17, 18] and acces-
sibility [44] value. Finally only best 10 epitopes from each
class (MHC - I and MHC - II) were retained along with
their respective HLA alleles.
Structure prediction of epitopes and docking study
Docking of T-cell class specific epitope on known binding
site (PBG: peptide binding groove) of respective MHC
class specific PDB structure was performed for further
short listing. Optimized epitope structure was obtained
using HMM-SA (Hidden Markov Model-derived Struc-
tural Alphabet) [48] with OPEP (Optimized Potential for
Efficient protein structure Prediction) force field [49].
2X4O and 1DLH were used as peptide targets for MHC
class I and II respectively. Both these targets were in com-
plex form with inhibitors. Structure with single binding
site and free from inhibitor was procured using VMD
interface [27]. Binding sites of each target was mapped in
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presence of inhibitor using NACCESS procedure [44].
Docking of above epitopes (10 from each class) onto its
respective targets (2X4O and 1DLH) were performed
using PatchDock server [50] along with input of com-
puted binding site. Epitope-receptor complex was then re-
fined using FireDock [51] server. Best four epitopes from
each class were selected on the basis of energetics and
interaction criteria.
Results
Like other countries in Asia [2, 8], JEV mediated acute
encephalitis syndrome and associated damage and death
in patients are the major health concern in India in
different states including WB [3, 4, 9]. The report of co-
circulation of GI with GIII in the district of Midnapur of
WB increases the risk of possible outbreak in the local-
ity. The appearance of the former was documented even
when Government aided regular vaccination program
was in vogue [3]. Such threatening genotypic transition
and failure of neutralization raise the possibility of crit-
ical mutations in envelope glycoprotein. In this study we
therefore investigate substitutions in E protein of GI
strains (Ishikawa, JEV28, JEV21 and JEV45) in reference
to the GIII vaccine strain (SA14-14-2).
E protein of GI strain acquires domain specific
substitutions
Which substitutions contribute to the transition from
existing GIII to emerging GI? To check this we have
presented observed substitutions in E protein of GI
isolates in Table 1 along with reference GIII strains.
Ishikawa, a typical GI isolate that caused outbreak in
Japan in 1994 and possesses similar mutations at homolo-
gous positions as WB isolates is also included for compari-
son purpose. Six mutations: K138E, V176I, A177T in
Domain I and F107L, H264Q, M279K in domain II of E
protein (Table 1, marked with a sign) are common in all
the GI isolates. They are also present in virulent GIII strain
SA14 (Table 1: column 8) from which the live attenuated
non-virulent SA14-14-2 strain was derived. Notably, north
India epidemic (in 2005) strain GP78 (ID AF075723) [1]
and recent GIII isolates (JEV46 and JEV47) from WB [4]
also contain the above six mutations. As these mutations
in E protein are common in SA14, GI and GIII virulent
isolates, net mutations in our GI isolates are counted
without them. However following points are note-
worthy from the Table 1: i] WB isolates have similar
positional substitutions as earlier Japan isolate (Ishikawa)
which has highest number of mutations in all three
domains of E protein, ii] JEV28 (2010) has fewer muta-
tions in most immunogenic domain III than JEV21
(2010) and JEV45 (2011). Substitutions V372L, M374I,
G388K, W396R are absent in JEV28, iii] four amino
acid changes in PDB (3P54_A) sequence relative to
UNIPROT one (ID P27395): K138E, V176I, F107L and
M279K were considered as mismatch [52].
To check domain distribution of net substitutions
(Table 1) of E protein, we have presented the following
Figure (Fig. 1). Several points are noteworthy from the
Figure. Firstly as we move from DI to DIII, substitution
frequency increases both for Ishikawa and JEV45 iso-
lates. The later, just one year younger than JEV28/2010,
is seen to acquire almost identical loci specific substitu-
tions as Ishikawa/Japan/1994. Secondly, as far as total
substitutions are concerned, Ishikawa dominates over
both JEV28 and JEV45. Finally, relative to JEV28 three
additional substitutions in JEV45 are seen in domain-III.
The domain is reported to be most immunogenic [53].
Structural insight into E proteins of GI isolates
The ecto domain of E protein is composed of 406 residues
that contains majority of the antigenic determinants. The
sequence identity of E protein of Ishikawa, JEV28 and
JEV45 are 94.8, 96.8 and 95.8% respectively relative to
SA14-14-2. Primary and secondary structural properties
of E protein of these GI isolates (Ishikawa, JEV28 and
JEV45) are compared with reference sequence (SA14-14-
2) in Fig. 2. It is seen that most of physicochemical prop-
erties, except GRAVY (Grand Average Hydropathy), net
charge and helix content remain almost similar as refer-
ence. These properties show modulation among GI iso-
lates. For example, while in Ishikawa and JEV28, GRAVY
decline, net charge of Ishikawa and JEV45 show an in-
crease. Although Ishikawa remains unaffected, coil to
helix transition is apparent for both JEV28 and JEV45.
Homology modeling allows gaining structural insight
from protein sequence [54] which further helps to extract
structural information [55, 56] including prediction of
conformational epitopes [57], localizing linear epitopes
[42] and prediction of the effects of SNPs via thermo-
dynamic cycle of folded and unfolded states of wild and
mutant proteins [58]. In present study, we developed a
total of 18 model structures (3 plus 15) for ecto domain
of E protein. The first three models are of E protein of
Ishikawa, JEV28 and JEV45 isolates. The rest 15 are
models wherein each structure possesses single positional
mutation (as in Table 1) with reference to the vaccine strain,
SA14-14-2. While the former three are useful for general
structural characterization of substitutions and epitopes, the
later are crucial for understanding the effect of SNP on over-
all conformational stability of protein, and its disease associ-
ation in relation to protein function. Homology models
were obtained by the use of advance modules of Modeller
v9.11 [24] followed energy minimization using CHARMM
force field of NAMD package [26] in presence of explicit
water as solvent with appropriate disulfide bond patching.
Models thus obtained were evaluated as earlier procedures
[20–23]. Topology of each model was compared with that
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of template by superposition of Cα atomic coordinates and
the average RMSD (Root mean square deviation) value was
found to vary in the range 1.12–1.44 Å. Absolute per residue
sum of surface area by NACCESS [44] procedure for tem-
plate is seen to be 40.1 Å2 and that for models (Ishikawa,
JEV28 and JEV45) vary between 42.9 and 43.7 Å2. In the
former, frequency of buried residues is seen to be 161 and
that for models vary between 160 and 161 when threshold
for core is set to ≤ 20 Å2 value. Detailed comparison
between template and models on salt bridges and its
energetics were performed using our laboratory developed
software [33–35]. Frequency of salt bridges (19 to 23) of
models and side-chain specificity of their partners remain
almost similar (≥75%) as template (data not shown).
Model structure of Ishikawa, JEV45 and JEV28 are
presented in Fig. 3a, b and c respectively. Each of these
structures highlights substituted residues (Table 1), disul-
fide bonds and domains (as DI, DII and DIII). Domain I is
the middle domain that (Fig. 3, red colored region recon-
stituted by 127 residues in three stretches: 1–51, 135–193
and 283–299) possesses nine stranded β-barrel structure
with two disulfide bonds (C3-C30 and C190-C287) and
model specific amino acid substitutions (N2H, N2T,
A177T, Y183F and R193K). It also contains the con-
served glycosylation site (N154). Domain II (yellow
colored) is the distal domain which forms extended
structure of 172 residues constituted by two regions
(52–134 and 194–282) of E protein. It is stabilized by
Table 1 List of domain specific mutations in E protein of GI isolates in reference (Ref) to GIII strains
Genotype I (GI) Genotype III (GIII)














Domain I N–2H . + + + N N N
N–2 T + . . . N N N
Y183F + . . . Y Y Y
R193K + . . . R R K
K138Ea (+)a (+)a (+)a (+)a Kb E K
V176Ia (+)a (+)a (+)a (+)a Vb I V
A177Ta (+)a (+)a (+)a (+)a T T A
Domain II C-60Y + . . . C C C
N103K + + + + N N N
F107La (+)a (+)a (+)a (+)a Fb L F
T129M + . . . T T T
A222S + + + + A A A
G244E + + + + G G G
G261S . + + + G G G
H264Qa (+)a (+)a (+)a (+)a Q Q H
M279Ka (+)a (+)a (+)a (+)a Mb K M
Domain III V315A + + + + V V V
S327T + + + + S S S
A366S + . . . A A A
V372L + . + + V V V
M374I + . + + M M M
G388K + . + + G G G
W396R + . + + W W W
Total mutations 21 13 17 17 4 6 Ref
Net mutations 15 7 11 11 - -
Amino acids marked with bsign in 3P54 have been identified as mismatches between PDB and UNIPROT sequence (P27395)
All comparisons are made for first 406 residues of E protein (ecto domain). All three GI isolates of Midnapur/WB are taken with earlier Japan strain (Ishikawa). In
GIII category, three sequences such as 3P54_A, virulent SA14 (ID M55506) and attenuated non-virulent SA14-14-2 (ID JN604986) are considered. + Sign indicates
presence and dot indicates absence of mutations respectively. (+) indicates category of reported neurovirulent mutations [13]. Identical neurovirulent mutations of
present isolates as SA14 are identified witha sign
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three disulfide bonds (C60-C116, C92-C121 and C74-
C105). This domain contains a total of seven substitu-
tions (see Table 1) with respect to the template (C60Y,
N103K, T129M, A222S, G244E, G261S and H264Q).
Fusion loop which is 13 residues long is shown by
purple color (at tip of Domain II) is needed for pathogen-
esis, infectivity and broad range antibody cross-reactivity
[52, 59]. It is highly conserved among all flaviviruses.
Domain III (blue colored globular domain) of the
model contains 100 residues (300–399) and forms typ-
ical immunoglobulin like fold at the C-terminus of the
ecto domain of E protein. This domain possesses one
disulfide bond (C304-C335) and seven substitutions
(V315A, S327T, A366S, V372L, M374I, G388K and
W396R). In this domain a tripeptide sequence RGD
(387–389; blue colored) form a motif which is believed
to play role in receptor interaction [5, 6, 60].
Although all models were evaluated using multiple
authentic procedures [20–23], results for the model
JEV45 is shown in the Right panel of the Fig. 3. Ener-
getic profile of the model (green trace) and the template
(red trace) are seen to be almost identical when plotted
as a function of residue position as obtained by ANOLEA
[61] (Fig. 3: D1) and VERIFY3D analysis [31] (Fig. 3: D2).
Ramachandran plot for main chain dihedral angles and
PROCHECK analysis [29] (Fig. 3: D3 and D4 respectively)
show amino acid residues, occupying core (92%) and
allowed (8%) regions.
Disease relation of substitutions
There are a maximum of 15 substitutions for GI isolates
apart from six reversal type (Tables 1 and 2). Are all these
substitutions lethal? How could they be related with pro-
tein function and disease association? To resolve this, we
present results of sequence and structure based prediction
of the effect of these SNPs in Table 2. Sequence based pre-
diction identify fatal substitutions as D and normal as N
based on score. Structure based method computes overall
conformational free energy change (ΔΔGWT→Mu) in
Kcal mol−1. These results (Table 2) show that only 4 of
15 mutations are lethal, disease associated and cause
protein malfunctioning. Rest 11 substitutions are normal
and non-disease associated. In this group of muta-
tions, +0.50 ≤ ΔΔG ≤ +2.00 and −2.00 ≤ ΔΔG ≤ −.50
categories are also observed.
One of the fatal substitutions (from sequence based
methods) i.e. N103K is seen to be common in all GI
isolates (Table 1). It is present in the fusion loop region
(Fig. 3) which is known to initiate host-virus interaction
and eventual viral entry. Two of the fatal substitutions i.e.
G388K and W396R are common for JEV21, JEV45 and
Ishikawa but absent in JEV28. Both these substitutions are
present in antigenic domain III of E protein (Fig. 3). The
substitution C60Y is only present in Ishikawa/Japan
isolate but not in any of the WB isolates. Notably C60 is
involved in the formation of disulfide bond in domain II.
Unlike normal, these 4 fatal substitutions show high
change of overall conformational free energy of which
G388K and N103K are positive and that in case of
W396R and C60Y are negative.
Epitope prediction
Envelope glycoprotein of JEV is 500 amino acids long of
which ecto domain constitutes about 406 residues. The
protein has been the major focus for immunoinformatics
studies for its neutralizing activity and antigenic cross
reactivity from different flaviviruses [62, 63]. In fact
clathrin-mediated viral internalization was reported to
be guided by the protein. At present the only available
Fig. 1 Comparison of net substitutions for each domains and total
of E protein among JEV28 (yellow), JEV45 (red) and Ishikawa isolates
(cyan). JEV21 is not included in the plot as it is identical to JEV45
Fig. 2 Residual plot of average physicochemical properties for GI isolates
(Ishikawa, JEV28 and JEV45) in reference to SA14-14-2. Analyses were
performed using PHYSICO [17] and PHYSICO2 [18] programs with an
input of E proteins of SA14-14-2, Ishikawa, JEV28 and JEV45 in FASTA
format. Percentile difference for each property was computed against
the reference data and plotted using SYSTAT Sigma Plot v11.0
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vaccine for prevention of JEV mediated AES/JE is de-
rived from live or inactivated form of GIII strain SA14-
14-2. However, the efficacy of immunization with the
current vaccine was questioned due to the fact that pre-
vaccinated patients showed symptoms of JE/AES with
co-circulation of GI strain in their serum [4, 10]. Such
reports of emergence of GI strain from the pool of GIII
in Asian countries signaling for design of high selective
epitopes.
B-cell epitope prediction
B-cell epitopes are effective for induction of neutralizing
antibody in relation to the viral entry. Identification and
characterization of these epitopes would help in design
of vaccine. B-cell epitopes having high prediction score,
low model energy (i.e. high conformational stability),
high average accessibility to the surface of protein and
high average conservation were selected (Fig. 3). Our
predicted epitopes (Table 3) show overlap with predeter-
mined epitope segments [64]. 7 of 8 epitopes (Table 3)
seen to harbor GI specific substitutions (Table 1) and
four of these seven epitopes namely VEMEPPFGD-
SYIVVGRGDKQ, GWGKGCGLFGKGSIDTCAKF, H
WHKAGSTLGKAFSTTLKGA and IEASQLAEVRSYYY-
HASVTD are seen to contain fatal substitutions.
Linear epitopes are predicted from sequence of E protein
[42]. Each epitope segment possesses specific folds or top-
ology in three dimensional structure of the protein. We
have localized all these linear epitopes in the structure of
which the epitope GWGKGCGLFGKGSIDTCAKF is pre-
sented in Fig. 4 AII. It is seen that the epitope covering
almost entire region of the fusion loop (residue 98–110)
which is important for viral infectivity [52]. Further, it is
exposed to the surface of the protein. Ab initio structural
analyses of these epitopes are performed using PEP-FOLD
method [43]. The model energy as obtained from this
analysis is presented in Table 3. Negative value indicates sta-
bilized structure (Table 3, column 4). Typical structures of
selective fatal epitopes are also shown in the Fig. 4B I and II.
Although fatal mutations are seen to be populated in lin-
ear B-cell epitopes, their occurrence in conformational B-
cell epitopes would be more relevant as sequentially distant
Fig. 3 Backbone Cα-traces of homology model (a for Ishikawa, b for JEV45 and c for JEV28) of the ecto domain of PM0080325, PM0080324 and
PM0080323 respectively. Domain I (red), domain II (yellow) and domain III (blue) are shown in different colors. Fusion loop (purple) and substitutions
with respect to the template (SA14-14-2) are highlighted in each of the model based on their occurrence (see Table 1). Disulfide bonds (green) are also
highlighted in each of the model based on their occurrence and only labeled in case of JEV45. Comparison of ANOLEA-profiles [61] of PM0080324
(green trace) with template (red trace) (D1), VERIFY3D (D2) analysis [31] and Ramachandran plot (D3) of main chain dihedral angles (core region is
outlined in deep blue and allowed region in red) for residues (glycine as green circle and non-glycine as pink points) of the model along with PRO-
CHECK [29] analysis (D4) are presented for model validation
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residues form a three dimensional shape for binding a
receptor [65]. We presented conformational epitope in
Fig. 4 AI. It is seen that residues forming conformational
epitopes are localized at three distinct region of E protein:
two in domain II and one in domain III. The fatal mutations
are seen to fall in these regions with very high specificity
(≥80%). Interestingly three of four fatal mutations (N103K,
G388K and W396R) are populated both in linear (Table 3)
and conformational epitopes (Fig. 4 AI). Further, in the later
case, mutant residue has been a part of one contiguous
stretch instead of distantly and singly spaced residues com-
ing in close proximity. Do these fatal mutations in peptide-
epitopes affect overall topology? To check this we compared
3D structures of wild-type and mutant-type peptide-
epitopes (Fig. 4 BI and II). It is seen that the later undergoes
large conformational change relative to the earlier as re-
vealed by their RMSD values (Fig. 4 BI and II). RMSD of
388K.pdb (MU) =8.2 Å w.r.t. 388G.pdb (WT) and RMSD of
396R.pdb (MU) =10.6 Å w.r.t. 396W.pdb (WT).
T-cell epitope prediction
In adaptive immune response, T-cells mediated prolif-
eration, secretion of cytokines (that stimulate antibody
production by B-cells) and apoptosis are resulted when
a ternary complex of (MHC-I/II)—(peptides)—(TCR-
CD8+Tc/CD4+Th) is formed. T-cell-mediated immunity
is essential for controlling infection of a variety of
mammalian cells by flaviviruses. During viral infection,
the expression of both MHC-I and MHC-II molecules
increases and the functional CD8+T cells provide pro-
tection by direct viral clearance whereas CD4+T cells
provide protection by eliciting protective antibody re-
sponses as well as by generating both B cell and CD8+
T cell memory responses. Flavivirus E protein is the
major target of immune responses and has been shown
to use both for MHC-I/CD8+ T cell as well as MHC-II/
CD4+ T cell specific epitope prediction [62, 66–69]. In
this study, we use IEDB Analysis Resource v2.14 [46]
for prediction of T-cell epitopes.
Table 2 Sequence and structure based evaluation of the effect of mutations (Table 1)
Sequence based prediction Structure based prediction
Mutation SIFT PHD-SNP SNAP META-SNP SDM
Score Effect Score Effect Score Effect Score Effect ΔΔG
Kcal Mol−1
Domain I N002H 0.500 N 0.056 N 0.180 N 0.115 N +0.01
K138Ea 1.000 N 0.121 N 0.185 N 0.111 N +0.52
V176Ia 0.400 N 0.047 N 0.160 N 0.090 N +0.22
A177Ta 1.000 N 0.042 N 0.105 N 0.063 N −0.17b
Y183F 0.200 N 0.488 N 0.525 N 0.367 N +1.79
R193K 0.450 N 0.490 N 0.340 N 0.414 N −0.81
Domain II C060Y 0.000 D 0.935 D 0.800 D 0.882 D −2.33
N103K 0.000 D 0.833 D 0.780 D 0.771 D +1.61
F107La 1.000 N 0.218 N 0.310 N 0.155 N −0.97
T129M 0.070 N 0.106 N 0.410 N 0.143 N +0.86
A222S 0.420 N 0.177 N 0.115 N 0.162 N −0.77
G244E 1.000 N 0.070 N 0.215 N 0.065 N +1.85
G261S 0.200 N 0.152 N 0.105 N 0.134 N +1.74
H264Qa 0.074 N 0.074 N 0.225 N 0.078 N −0.75b
M279Ka 0.390 N 0.159 N 0.255 N 0.121 N −1.97
Domain III V315A 0.620 N 0.066 N 0.400 N 0.094 N −1.63
S327T 0.820 N 0.067 N 0.175 N 0.103 N +0.97
A366S 0.740 N 0.190 N 0.235 N 0.185 N −1.18
V372L 0.310 N 0.129 N 0.245 N 0.164 N −0.79
M374I 0.540 N 0.225 N 0.365 N 0.169 N +0.08
G388K 0.010 D 0.910 D 0.775 D 0.793 D +3.00
W396R 0.000 D 0.841 D 0.865 D 0.819 D −2.48
D disease, N normal; aindicates these six mutations are not GI specific but also present in SA14, GIII isolates with reference to vaccine strain SA14-14-2 (Table 1);
bindicates ΔΔG was calculated in reverse mutation form i.e. T177A and Q264H as WT E protein possesses T and Q at these positions respectively Server based four
independent methods for sequence of ecto domain of E protein and Site Directed Mutator (SDM) [41] method for structure of all isolates was used for the
purpose (see Materials and Methods for details)
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Three score criteria were followed for screening of these
peptide epitopes: a] MHC-I binding score, b] proteosomal
cleavage score and c] antigenicity score. MHC-I presents
endogenous peptide epitopes to the CD8+ cytotoxic T cell
receptor (TCR). Table 4 presents predicted MHC-I (also
known as HLA in human) endogenous peptides of E pro-
tein. HLA-restriction of each peptide was achieved by
setting a lower cutoff for binding score (≤20) and hence
better complex formation of peptide with respective allele
of HLA is expected. Highly screened peptide epitopes are
seen to harbor JEV genotype-I specific lethal substitutions
(Table 2) which are pointed out by bold fonts with under-
line. The epitope YIVVGRKDK is most antigenic and
harboring the G388K lethal substitution (Table 4). The
alleles, with which it associates are HLA-A*03:01, HLA-
A*11:01 and HLA-A*68:01 which are known to populate
among Asian population [70]. Similar details are presented
for other epitopes.
JEV E protein was also used for prediction of MHC class
II specific epitopes using the above server. MHC-II pre-
sents exogenous peptide epitopes to the CD4+ T-helper
cell (Th) receptor (TCR). As MHC-II presents exogenous
epitope peptides, cleavage score is not available in such
prediction (Table 5). Like MHC-I, GI specific lethal substi-
tutions are also shown in the selected peptide epitopes.
Allelic association against each epitope is achieved by set-
ting lower cutoff for MHC II binding. Lower binding score
is the indicator of better complex formation between pep-
tide epitope and MHC molecule. Highest antigenicity
score and very low MHC- II binding score is observed for
the epitope GFTDRGWGKGCGLFG which associates
mostly DRB1 class of alleles of type 3, 8 and 11.
Prediction of T-cell epitopes are performed using
sequence of E protein in IEDB server [46]. How these epi-
topes are structurally compatible in interaction with
peptide binding groove (PBG) of their corresponding
MHC molecules? To check this we evaluated energetics of
docked-complex of epitope. We further checked pos-
itional Shannon conservation [17, 18] and average side-
chain accessibility [44] of these peptide epitopes. Table 6
presents average conservation (Table 6: column 5), acces-
sibility (column 6), epitope conformational stability (col-
umn 7) and binding affinity for the PBG of MHCs
(column 8 through 11). When positional Shannon entropy
(with BLOCK length ≥70) ≤0.50, those positions are taken
as conserve. In our case, observed variability for epitopes
are seen to be far less and even zero (column 5). All
Fig. 4 B cell specific conformational antigenic determinants (AI) and linear epitopes (AII). (AI, AII) In each case domains of E protein are presented
by different colors (i.e. domain I red, domain II silver and domain III green). (B) Representative Epitope pairs (BI for G388K and BII for W396R) for
comparison of main chain topology of wild-type (blue) and mutant-type (red). The wild-type (yellow) and mutant (cyan) type residues are shown
in stick formats. Each of this peptide structure was generated using PEP-FOLD [43] followed by normalization and fixation of charge and potential.
RMSD of mutant structure was computed in reference to its wild-type. F-L: Fusion loop; RGD-L: RGD loop
Table 3 B cell specific antigenic peptide epitopes short listed
from a large set of initial population based on their antigenic












325 ELTYSGSDGPCKIPIVSVAS 0.986 −23.71 22.8 0.01
372 VEMEPPFGDSYIVVGRGDKQ 0.977 −24.54 37.1 0.02
100 GWGKGCGLFGKGSIDTCAKF 0.956 −29.81 42.1 0.02
69 STVARCPTTGEAHNEKRADS 0.926 −12.95 59.3 0.01
395 HWHKAGSTLGKAFSTTLKGA 0.876 −23.38 97.2 0.02
121 CTSKAIGRMIQPENIKYEVG 0.854 −18.21 38.2 0.06
349 TPVGRLVTVNPFVATSSSNS 0.923 −20.55 39.9 0.04
48 IEASQLAEVRSYYYHASVTD 0.967 −32.65 31.4 0.06
NACCESS program [44] was used to generate residue accessibility data. Then
average accessibility was computed using side chain relative accessibility
values. Variability was calculated using full length E protein sequences (total
50) and positional Shannon entropy (H) [17, 18] was computed for each
homologous position. The Av. Variability is the average of all residues value.
Average is made up to 404 residues as the model has 404 residues
like template
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epitopes are seen to be solvent exposed as their average
accessibility is seen to be >20 (column 6). Peptides struc-
tural parameter i.e. conformational stability is seen to be
negative (column 7). However, greater stability for MHC -
II specific peptides seems to be related with sizes of pep-
tide epitopes. Docking based energetics analyses are pre-
sented in column 8 through 11 (Table 6) are for overall
stability (GE), Van der Waals (VDW), atomic contact en-
ergy (ACE) and hydrogen bonding (HB) interactions in
Kcal Mol−1 respectively. All these energy of interactions
are highly negative and hence stabilizing.
To check the interaction of epitopes with the peptide-
binding-groove (PBG) of MHC class I and MHC class II
representatives, typical complexes for each class is pre-
sented in the Fig. 5. Figure shows two views from each
class specific interaction along with mutated residue
(white), peptide binding site (PBG). PBG is formed by
two domains (α1 and α2) of α-chain (homo dimer) in
MHC - I, in MHC-II it is hetero dimer and formed by
α1and β1 domains of α and β chains respectively.
Diversity in T-cell epitopes
All T-cell epitopes (Tables 4 and 5) are conserved in nature
as judged by their positional Shannon Entropy values.
These selected epitopes of GI strain of JEV from WB
(Midnapur) and Japan harbor fatal substitutions namely:
C060Y, N103K, G388K and W396R. How these epitopes
are evolved in other geographical locations? To check the
diversity in these epitopes a total of 613 E protein
sequences were grouped into 8 geographical regions
(China-228, Japan-113, Taiwan-79, India-66, Korea-35,
Thailand-33, Indonesia-27 and Vietnam-32) and subjected
for IEDB-Conservancy analysis. The result is presented in
(Additional file 1) for MHC - I and (Additional file 2) for
MHC - II epitopes. Following points are noteworthy
from the observation: i] for all geographical regions







(Human Leukocyte Antigen [HLA] specific)
Antigenic Scorec






95 GFTDRGWGK 4.4–15.5 0.85 HLA-A*03:01,HLA-A*11:01,HLA-A*29:02,HLA-A*30:01,HLA-A*33:03,
HLA-A*31:01,HLA-A*68:01,HLA-A*74:01,HLA-C*04:01
1.4597
382 YIVVGRKDK 6.4–6.6 0.92 HLA-A*03:01; HLA-A*11:01;HLA-A*68:01 2.5185
394 HHRHKAGST 8.9–13.7 0.70 HLA-B*07:02, HLA-B*14:02 0.5088
aPercentile score vary in allele specific manner. The lower the score better is the binding specificity [46]. The range of scores was obtained by setting cut off.
bProteosomal cleavage score is the average of two kinds of scores: constitutively expressed type and INF-γ induced type. cAntigenic score was computed using
Doytchinova and Flower's (2007) method [47]
Three score criteria were followed to screen the epitopes: MHC class I binding score, proteosomal cleavage score and antigenicity score. Association of HLA alleles
for each epitope was determined by a cut off for percentile rank value ≤ 20.0. Epitopes were further checked for their efficacy in interactions at the peptide
binding groove (see below)





(Human Leukocyte Antigen [HLA] specific)
Antigenic Scoreb





95 GFTDRGWGKGCGLFG 5.37–17.95 DRB1*01:02,DRB1*03:05,DRB1*07:03,DRB1*08:01,DRB1*11:01,DRB1*11:28,
DRB1*13:05,DRB1*13:21,DRB1*15:02,DRB1*15:06,DRB5*01:05
0.9232








aPercentile score vary in allele specific manner. The less the score better is the binding. The range of scores was obtained by setting cut off. bAntigenic score was
computed using Doytchinova and Flower's (2007) method [47]
Epitopes were further checked for their efficacy in interactions at the peptide binding groove (see below)
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and for all epitopes, large proportion of these peptide
epitopes (Tables 4 and 5) remain similar as GIII type
(SA14-14-2), ii] observed SNPs in these epitopes
(namely: C060Y, N103K, G388K and W396R) in
studied GI-strains (JEV28, JEV21 and JEV45 in WB
and in Ishikawa in JAPAN) are not unique but other
types of SNPs are also seen. The GI strains of Midnapur/
WB/India are only examples (of all 65 Indian strains) that
contain similar fatal SNPs as earlier Japan GI strain
(Ishikawa), iii] these SNP harboring epitopes are mostly
related with the genotypic transition from III to I and
V/II. For example in China the epitope YCYHASVTD
constitutes 221 WT (i.e. GIII) and 7 mutant types.
Again, 6 of these mutant types are from GI and 1 is
from GV, iv] frequency and position of SNP in these
epitopes vary for geographical regions and v] finally GI
isolates of Midnapur are seen to be similar to earlier
Ishikawa/Japan type but vary greatly from other Indian
and non-Indian types.
Discussion
In spite of the availability of vaccine, JE/AES cases and
deaths are frequent in different districts of West Bengal
state, India. Emergence of GI and its co-circulation with
GIII was reported for the first time in the district of
Midnapur, WB even when patients were preimmunized
with SA14-14-2 [3, 4]. Clinical symptoms and severity for
GI mediated infection vary greatly from that of GIII which
might involve viral and host factors. E protein plays crucial
role in viral infectivity, virulence, host tropism and
antigenicity [12]. In this context the reason of this
genotypic transition and the study in relation to the
development of GI specific vaccine are to be worked
out. We apply in silico procedure using E protein
sequence and its 3-dimentional models i] to identify
critical among all acquired substitutions, ii] to work-
out epitopes harboring these critical substitutions and
iii] to gain insight into the development of vaccine
with potential in controlling GI cases.
Table 6 Energetics of docking complex formed between epitopes and PBG of MHCs along with their conservation, accessibility and
conformational stability values

















CGE GE VDWa ACE HB
MHC-I 1 59 YYYHASVTD 0.02 23.5 −4.70 −42.89 −16.11 −5.89 −4.74
2 95 GFTDRGWGK 0.03 50.4 −6.61 −28.87 −21.69 −4.29 −2.42
3 382 YIVVGRKDK 0.01 32.0 −5.52 −29.36 −11.13 −4.13 −1.95
4 394 HHRHKAGST 0.03 64.3 −5.84 −39.03 −14.41 −2.02 −7.97
MHC-II 1 55 EVRSYYYHASVTDIS 0.04 24.7 −16.96 −48.65 −15.18 −9.98 −2.92
2 95 GFTDRGWGKGCGLFG 0.02 57.9 −17.23 −46.57 −14.25 −5.75 −4.75
3 380 DSYIVVGRKDKQINH 0.04 34.9 −16.07 −53.97 −22.96 −1.11 −5.02
4 383 IVVGRKDKQINHHRH 0.00 36.8 −15.34 −52.90 −13.06 −3.63 −2.61
aVDW is the net stabilization due to Van der Waals interactions i.e. (attractive VDW – repulsive VDW); GE global stabilization energy, ACE atomic contact energy,
HB hydrogen bond, CGE coarse-grained free-energy of peptide-structure used for docking [49]
Fig. 5 Docking and structure based short listing of antigenic epitopes using human class I MHC (HLA-A i.e. 2X4O.pdb in a) and class II MHC
(HLA-DRB1 i.e. 1DLH.pdb in b) crystal structures. Typical sequence and structure of docked peptide (blue color A & B) with white one as mutated
residue. PBG indicates peptide binding groove which was mapped using NACCESS procedure [44] (see Materials and Methods for details). Two
views per MHC class are shown for better visualization of binding pocket and binding groove. Chains of both classes of MHCs are shown by
conventional notations
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Structural properties of models
The E glycoprotein of JEV is 500 residues long of which
452 residues form extracellular domains and rest 48 resi-
dues form intra-membrane region (in part of 21, 6 and 21
residues). The protein has pI in the neutral range with net
charge negative. It is predominantly β-sheeted. To gain
insight into structure and mutations, we developed high
precision models of GI isolates. Initial models are energy
minimized to remove unwanted steric clash and to obtain
global minimal structure. Multi procedure validations are
done to assess quality. Low average RMSD (1.12–1.44 Å) of
models indicates almost identical main chain topology.
Absolute residue-surface-area and frequency of core-
residues of models and template were almost identical.
These assessments along with arrangement of secondary
structures, specificity in di-sulfide bonds of models are indi-
cative of well developed functional structure of the proteins.
Although similar, there exists fine structural difference
between models and the template. In template (from GIII)
there are 33 strands of 209 residues (51%) and that for
JEV28 (GI), for example, is 33 strands of 225 residues
(55%). Similar difference also exists in other models which
might have arisen due to genotypic variations due to substi-
tutions (Table 1). Salt bridges are formed when side chains
of acidic and basic residues are within ≤4 Å distance [71].
Similar specificity (≥75%) in these interactions in models
and in template further indicates that the geometry and
conformation of side chains are also well formed.
Acquired GI specific substitutions and inducer of GIII to GI
transition
GI isolates JEV28 (also JEV21) and JEV45 was discovered
from the Midnapur district of WB in 2010 and 2011 re-
spectively. These strains were isolated as co-circulation
cases in patient and were seen to be capable in escaping
the effect of vaccination with SA14-14-2. These patients
were thus developed JE clinical symptoms [3, 4, 10, 11].
These isolates show similar locus specific mutations as
Japan outbreak-GI-isolate (Ishikawa) in 1994. Our focus is
to identify substitutions that may have relation with GIII
to GI transition.
Mutations pertaining to neurovirulence and neuroinva-
siveness seem to be genotype independent properties.
These phenotypic properties depend on substitutions in E,
other structural and non-structural proteins of JEV [72].
Cao QS, et al. (2011) [12] showed that the sequence of E
protein of their GI isolate is identical as virulent GIII strain
(SA14) but differ from SA14-14-2 at 8 different positions
(F107L, K138E, V176I, A177T, H264Q, M279K, V315A
and R439K) which they logically considered to be respon-
sible for virulence phenotype of their isolate. Exactly similar
results were also obtained both for GIII (JEV46 and JEV47)
and GI (JEV28 and JEV45) isolates [4] indicating the obser-
vation is genotype independent. It is noteworthy that E
protein of virulent (SA14) and non-virulent (SA14-14-2)
strains differ by first 6 mutations (Table 1, marked with a
sign) [73]. Neuroinvasiveness could largely be related with
the substitutions in other proteins but not in E protein.
Nerome R, et al. (2007) and Cao QS, et al. (2011) [12, 13]
reached to the same conclusion as far as neuroinvasiveness
is concerned. Moreover, in reference to GP78/India [1] it
was concluded that SA14-14-2 needs E244G, A315V and
S366A for complete neurovirulence [72]. Nevertheless
crucial substitutions that cause the transition of existing
GIII to newly emerged GI (JEV28 and JEV45) in Midnapur
district and allow escaping the effect of vaccination
remained unanswered.
Table 1 compares substitutions in JEV28 and JEV45 (also
JEV21; Ishikawa/Japan/1994) with non-virulent (SA14-14-
2) vaccine strain (also virulent SA14; PDB ID 3P54). As
mentioned above, mutations at positions: 138, 176 and
177 (in DI) and 107, 279 and 264 (in DII) emerge due to
attenuation of virulent phenotype. SA14 and SA14-14-2
also differ at these positions (Table 1, mutations marked
witha sign). Additionally the ecto domain needs G244E,
V315A and A366S substitutions for virulent phenotype
(see above). It therefore indicates that these mutations are
neither related to the transition of GIII to GI nor with the
escape of vaccine effects. Thus to gain insight into the
effect of homologous substitutions that may induce emer-
gence of GI, we attempted rigorous sequence [37–40] and
structure [41] based approaches using sequence and struc-
ture as input respectively. Out of all substitutions, only
C60Y, N103K, G388K and W396R are GI specific and
disease associated. As N103K is the only one which is
common in all our GI isolates and showing disease associ-
ation, it might be crucial for GIII to GI transition and
escaping of GIII vaccine effect. It is present in the fusion
loop region (98–110) which is crucial for viral infectivity
[52, 59]. JEV45 (also JEV21) contains two additional GI
specific fatal substitutions (G388K and W396R) that are
absent in JEV28. C60Y is only present in Ishikawa strain.
In silico site directed free energy evaluation [58] shows
that C60Y and W396R are destabilizing whereas N103K
and G388K are stabilizing. C60Y destroys one conserved
disulfide bond (between C60 – C116) and W396R causes
removal of conserved Tryptophan residue. The stabilizing
effect of N103K and G388K might be due to the side
chain of Lysine that possesses a long flexible hydrocarbon
tail with positive charge at its end which might facilitates
stabilizing electrostatic interactions. Further G at 388 of
DIII/E protein is present in the RGD motif [6, 60] import-
ant for cell-cell interaction. Substitution of such conserved
glycine that imparts flexibility is known to have worst
structural effect [74]. Overall, these 4 SNPs that are ac-
quired in the course of viral evolution seems to be crucial
for GI specific characteristics of E protein of which
N103K acts as initiator for transition.
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Other substitutions such as N2H, N2T, T129M,
A177T, Y183F, R193K, A222S, G244E, G261S, H264Q,
V315A, S327T, A366S, V372L and M374I are non-
disease associated. They could be divided into two cat-
egories: neutral and non-neutral-non-disease associated.
While the former do not affect conformational properties
of mutant protein the later does to some extent.
B-cell epitopes harboring fatal substitutions and are
crucial for neutralizing antibody
Major challenge remains to understand the escape of
neutralization of GI specific infection upon vaccination
[3, 4]. The purpose of vaccination is to induce prolifera-
tion of neutralizing antibody that in turn is expected to
neutralize viral infection. The reports of co-circulation
cases (GIII with GI in patients) in the district of Midnapur/
WB have been a serious concern. In this end the substitu-
tions F107L, K138E, V176I, A177T, H264Q, M279K,
G244E, V315A and A366S are unlikely to be responsible
as i] these are related with virulent phenotype and ii] are
observed both with GI and GIII isolates [4]. Prediction of
neutralizing epitopes harboring fatal SNPs would not only
help to understand escape mechanism but also be useful in
designing GI specific vaccine that might take care possible
GI-mediated outbreak in the region in near future. Our
studies shows that of all SNPs only 4 such as C60Y,
N103K, G388K and W396R are disease-associated of
which former two are in domain-II and the later two are in
domain-III of E protein which are the source of major anti-
genic determinants [53]. The question that are these SNPs
present in our predicted population of B-cell epitopes. B-
cell epitopes, both configurational (linear) and con-
formational (spatial), are thus predicted using authentic
web servers. Initial population of both these epitopes is
screened based on their scores. Linear epitopes were
further screened for: a] accessibility, b] epitopes model
energy and c] average conservation properties. It is in-
teresting to note that these highly screened B-cell epi-
topes (Table 3) harbor disease associated SNPs namely
C60Y, N103K, G388K and W396R. Of these four,
N103K in fusion loop, G388K in RGD loop and
W396R is in the N-terminal membrane attachment site
(NT-MS site) (Fig. 4 AI). These regions are known to
play important role for antigenicity and infectivity [75].
Their presence in both linear and conformational epi-
topes (in contiguous stretch of residues) indicates their
importance in the development of vaccine. Large varia-
tions of RMSD of GI specific lethal mutation harboring
peptide epitopes, point to the shift of wild-type (GIII
specific) specificity in the neutralization reaction.
The only lethal substitution N103K is present in
Midnapur/WB/JEV28 whereas Midnapur/WB/JEV21 and
Midnapur/WB/JEV45 contain N103K, G388K and
W396R. All these three isolates of Midnapur are newly
emerged as GI [3]. Sarkar et al. (2013) interpreted the
mutation G388K to be responsible “to escape from
antibody neutralization or neutralizing epitope” based
on physiochemical property and IC50 score for MHC-I
specific T-cell epitopes without confirming the presence
of the residue in B-cell epitopes. In fact B-cell epitopes
were not determined in the work. The authors have
applied similar approach for the substitution N103K.
The fact that substitutions at homologous positions
could be acquired either by natural selection that
affects protein function [76] or by genetic drift that im-
parts neutral effect [77] understanding the effects of
substitutions on protein function need careful criteria-
based evaluation. It may further be essential to confirm
the presence of these substitutions on epitope for un-
derstanding escape mechanism. However, apart from
the above linear epitopes, conformational B-cell epi-
topes (Fig. 4 AI) which are seen to be localized in most
antigenic domains (DII and DIII) of the protein are
seen to contain these above mentioned fatal SNPs with
very high scores. The fact that each of these SNPs is
seen to affect overall conformational stability of mu-
tated E protein (Table 2) the possibility of altered speci-
ficity in neutralization reaction could not be ruled out.
Taken together, it could be said that observation of
repeated co-infection cases [3, 4] might be due to al-
tered specificity of antigenic determinants harboring
these fatal SNPs. These epitopes would also be useful
for designing GI specific vaccine.
Fatal substitutions in T-cell epitopes
T-cell mediated immune response plays crucial role in
proliferation of both cytotoxic T-lymphocytes and cyto-
kines induced B-cell antibodies [78]. Length of MHC
class I specific epitopes are 8 to 11 amino acids long and
that for MHC class II is 13 to 17 amino acids long [78].
Unlike B-cell epitopes, selection of T-cell ones are MHC
classes and alleles specific. We selected only four epitopes
from each class following strict cutoff for MHC binding,
proteosomal cleavage (for MHC class I only) and antigenic-
ity score. Of all MHC class I epitopes, YIVVGRKDK pos-
sesses highest antigenicity and proteosomal cleavage score.
It contains the lethal substitution G388K in its RGD motif
which is known for host cell interaction [6, 60]. The substi-
tution, present in Midnapur (JEV45 and JEV21) and Japan
isolates (Ishikawa), is shown to affect overall conformational
stability of E-protein. Thus it may affect T-cell proliferation
and cytokine mediated B-cell antibodies production. Inter-
estingly the same substitution G388K is also present in
MHC class II specific epitope DSYIVVGRKDKQINH with
very high binding and antigenicity score. The first GI isolate
(JEV28) from Midnapur/WB contains only one lethal sub-
stitution i.e. N103K. It is present in the fusion loop of the E
protein which is important for viral infectivity. Our
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predicted MHC class (I and II) specific epitopes has been
GFTDRGWGK and GFTDRGWGKGCGLFG respectively
that contains the said mutation. The former has higher spe-
cificity (lower binding score and higher antigenicity score).
The fact that the patients, from which these strains were
isolated, were reported to escape the neutralizing effect of
GIII specific vaccine [4], these set of B-cell (see above) and
T-cell epitopes can be used as reference for development of
GI specific vaccine. Moreover other predicted epitopes that
harbor lethal substitutions (such as C60Y and W396R) are
also potential to alleviate GI specific danger [3, 4] from the
district of Midnapur (see below).
Major (A, B, C) and minor (G) class I type HLA alleles
that are associated with our selected epitopes are major
alleles for zoonotic viral infection [79]. Similarly, hap-
lotypes DRB1*04, DRB1*03, DRB1*08, DRB1*09 and
DRB1*11 are abundant in our class II specific epitopes.
These haplotypes were seen to be associated with zoonotic
viral infection [80, 81].
The selected B-cell and T-cell epitopes of GI isolates
of Midnapur/WB (JEV28, JEV21 and JEV45) are com-
pared with isolates from other geographical regions such
as China, Japan, Taiwan, Korea, Thailand, Vietnam and
Indonesia (see Additional files 1 and 2). The mutation
patterns of these epitopes are seen to be similar as
Ishikawa/Japan but differ for isolates from other geograph-
ical regions. The mutated populations of these epitope-
segments are very low (≤2%) and are mostly related with
genotypic transition from GIII to GI/GV/GII. For example
of 228 isolates from China for the epitope YCYHASVTD,
220 are of GIII type, 7 are GI and 1 is GV type (see
Additional file 1). Epitope-segments occupy different
parts of E protein sequence that may have differential
selection pressure from different geographical regions.
For example the epitope YIVVGRGDK (382–390) shows
more variants in Vietnam (7 of 32) than China (4 of 228)
isolates and no variations are seen in Thailand isolates
(0 in 33).
Conclusions
Our studies employ wide range of sequence and struc-
ture based in silico procedures on E protein of GI iso-
lates from Midnapur/WB to understand GI specific
lethal substitutions, its transition from the pool of GIII
strain of JEV and prediction of B-cell and T-cell epitopes
along with their diversity in Asian continent. Nine sub-
stitutions are commonly seen in the ecto domain of E
protein of GI and GIII isolates are largely act as deter-
minant of virulent phenotype of these GI isolates. 4 sub-
stitutions namely C60Y, N103K, G388K and W396R
are lethal and GI specific of which former two are in
domain II and the later two are in domain III. The
lethality largely related to the overall destabilization of
the protein, its malfunctioning and disease association.
These four substitutions affect most conserved region of
the E protein. While in domain II, C60Y destroys a con-
served di-sulfide bond, N103K occurs in the highly con-
served fusion loop. G388K disrupts conserved RGD
motif and W396R destroys most conserved tryptophan
residue in domain III. N103K, the only lethal mutation
which is common among all three GI/WB isolates
(JEV28, JEV21 and JEV45) and earlier Ishikawa/JAPAN
isolate, could be the reason for genotypic transition from
existing GIII to newly emerge GI isolate in the region.
Highly antigenic, top scored B-cell (both linear and
conformational) and T-cell (both HLA class I and II)
epitopes are seen to harbor these critical substitutions
and thus these subset of epitopes may act as reference
for design of GI specific vaccine. Although mutation
pattern vary, these subset of epitopes act as target site
for acquisition of genotypic transition related substitu-
tions for other isolates of Asian continent. Overall our
approaches highlight detailed aspects of immunoinfor-
matics and find applications in the context of other in-
fectious disease causing systems.
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